Alkem Laboratories is the fifth largest pharma company in the country and it generates 75 of the revenue from the domestic sales.But in general all the pharma companies generate most of the income by exporting to other countries.This company generates 25% of sales from international market.
In the price band of RS 1020 to 1050 the issue is priced at 25-26 times price to earnings compared for FY 2015 which is at a discount to the listed peers like CADILA,LUPIN and TORRENT which are trading at premium valuation.See the charts below for the Lupins PE as an example.
When compared to Lupin the IPO is trading at a discount so there is a scope for upside.
The financial results of Alkem laboratories is mentioned below for your reference.
So overall the companies is growing very well and there is some thing on the table for the retail investors to get if they subscribe for the ipo.
The below Links or reviews on the IPO might be helpful to know more details about the company.
No comments:
Post a Comment